Beacon is working with our client partner to raise awareness about low-lying lids (acquired blepharoptosis) and increase diagnosis and treatment with the first and only FDA-approved prescription eyedrop. This campaign speaks to both HCPs and patients through unbranded and branded channels to:
- Elevate awareness that low lying lids are often a real and noticeable condition that can impact field of vision, reading, driving, computer use, and other day-to-day activities
- Motivate both HCP and patient dialogue to actively identify and diagnose low-lying lids and prescribe appropriate daily treatment
- Position UPNEEQ® as the only once-daily prescription eyedrop that rapidly lifts low-lying lids to open eyes—a new standard for first-line treatment of this condition
